| Organiser : Bo Hu |
| Speakers : Bo Hu | Hélène Castel-gandolfo | Peng Yu | Michele Mondini | Pierre Saintigny |
Brief Teaser
"2021 Workshop on Cancer and Biomarkers" is hosted by School of Life Science and Technology of Xidian University and Engineering Research Center of Molecular and Neuro Imaging Ministry of Education, and co-organized by University of Evry (France), University of Paris-Saclay, University of Rouen Normandy. It is scheduled to be held on the October 20th, 2021 in the South Campus of Xi'dian University, Xi'an, Shaanxi Province. The theme of this conference are tumors and markers, focusing on molecular imaging, new anticancer drugs, nanoprobes, tumor biomarker detection, and clinical research of tumors. Participants from academic and medical institutions and industry will present and discuss their knowledge and perspectives on current and future cancer imaging, treatment and biomarkers. The conference aims to provide a wide range of interdisciplinary academic exchange platforms for scholars engaged in basic, applied and development research in related fields, and promote the in-depth development of related disciplines. There are eight report chance and hope they enjoy the meeting. The university can provide some lecture fees for the eight speakers. This conference will also adhere to the tenet of “Credit First, Warm and Thoughtful”, and warmly welcome domestic and foreign instruments and chemical reagent companies and enterprises to participate in and guide. The organizer of the conference solemnly promised to provide strong support for enterprises to display their image, develop the market, publicize the latest products and new technologies, and communicate with users on the spot. We are at Xi‘’an and we sincerely welcome you! |
| Organiser : Sylvain Fisson |
| Speakers : Jean-Michel Lagarde |
Brief TeaserInnovative biotherapies are on the rise and use biomedicines whose active ingredients are produced from living organisms and resulting from fundamental research in biotechnology. This includes antibodies, vaccines, viral vectors, stem cells and other therapeutic molecules produced from living microorganisms. Innovative biotherapies are closely linked to diagnostic and prognostic biomarker tools, as well as for therapeutic monitoring. The integration of these tools into the therapeutic arsenal allows for more efficient patient care and contributes to a better understanding of the pathophysiology of diseases. However, the basic aspects must not be forgotten and allow us to remain at the forefront of innovation in biotherapies. This webinar will therefore focus on all these facets of biotherapies, as well as future innovative projects, and will be illustrated with numerous examples of applications. |
| Organiser : Chanjuan XU |
| Speakers : Jianfeng Liu | Chanjuan XU |
Brief Teaser
The Huazhong University of Science and Technology from WUHAN (China) will lead 2 days of conferences prepared by the key-players from Academic, Medical, Investors and Industrial players to share the recent progresses and new innovative solutions in the field of cancer, ageing associated diseases. This 2-day program is part of the unique series of lectures prepared by the International Organizing Committee proposing 10 day of conferences spread over the year (www.icis.ibbs-services.com). During these 2 days, The Huazhong University of Science and Technology from WUHAN (China) will allow many participants, especially Chinese and French - Academic, Medical, Investors and Industrial players- in the field of cancer and ageing associated diseases to: (i) Present innovative research and therapeutic solutions from Bench to Market to prevent or cure cancer and ageing associated diseases (ii) Set-up novel scientific and medical contacts with Key opinion leaders (iii) Set-up one-to-one partnering meetings to favor innovative solution valorization (iv) Participate to educational sessions on cancer and ageing associated diseases and on research valorization. It will be held online on December 14 and 15, 2021 and co-organized with the support of the French Embassy in China, Huazhong University of Science and Technology, Université Paris Saclay, Université d’Evry, The French anticancer center Léon Bérard, the Sino French School of Oncology, and operated by International Bio-business services. Hoping to meet all of you on the meeting platform, we will work on our common wish to defeat cancer and ageing associated diseases as soon as possible. Dr Grégoire PREVOST & Professor Jianfeng LIU, Co-Presidents of the International Organizing Committee Grégoire PREVOST博士 & 刘剑峰教授 Dr Gregoire Prevost, CEO of CIPREVO |
| Organiser : Chanjuan XU |
| Speakers : Jianfeng Liu | Chanjuan XU |
Brief Teaser
The Huazhong University of Science and Technology from WUHAN (China) will lead 2 days of conferences prepared by the key-players from Academic, Medical, Investors and Industrial players to share the recent progresses and new innovative solutions in the field of cancer, ageing associated diseases. This 2-day program is part of the unique series of lectures prepared by the International Organizing Committee proposing 10 day of conferences spread over the year (www.icis.ibbs-services.com). During these 2 days, The Huazhong University of Science and Technology from WUHAN (China) will allow many participants, especially Chinese and French - Academic, Medical, Investors and Industrial players- in the field of cancer and ageing associated diseases to: (i) Present innovative research and therapeutic solutions from Bench to Market to prevent or cure cancer and ageing associated diseases (ii) Set-up novel scientific and medical contacts with Key opinion leaders (iii) Set-up one-to-one partnering meetings to favor innovative solution valorization (iv) Participate to educational sessions on cancer and ageing associated diseases and on research valorization. It will be held online on December 14 and 15, 2021 and co-organized with the support of the French Embassy in China, Huazhong University of Science and Technology, Université Paris Saclay, Université d’Evry, The French anticancer center Léon Bérard, the Sino French School of Oncology, and operated by International Bio-business services. Hoping to meet all of you on the meeting platform, we will work on our common wish to defeat cancer and ageing associated diseases as soon as possible. Dr Grégoire PREVOST & Professor Jianfeng LIU, Co-Presidents of the International Organizing Committee Grégoire PREVOST博士 & 刘剑峰教授 Dr Gregoire Prevost, CEO of CIPREVO |
| Organiser : Christian Cave |
| Speakers : Christian Cave | Olivier Lavergne | Pascal Marchand | Yongmin | Xin Meng | Long Ma | Huimin Qin | Sandra Oucher | Liu Fang | Luc Demange | Armel Diatta |
Brief Teaser
This webinar is set on the discovery of new small organic molecules as potential drug candidates. Medicinal chemistry is a common practice in pharmaceutical research and development. It describes the steps in the process from target definition, lead discovery and evaluation up first studies related to metabolism, pharmacokinetics and toxicology. Despite the development of biologics in recent years, the development of small molecules is still relevant today. (more than 90% of current on-the-market drugs are small molecules) Small molecule drugs are relatively simple chemical compounds and can be manufactured by chemical synthesis. The pharmacological activity, stability, and permeability of small molecules largely depend on their physico- chemistry proprieties. Small molecules can be effective enzyme inhibitors and allosteric modifiers and can target extracellular proteins or intracellular receptors in the cytosol, nuclei, and central nervous system. In addition, small molecule drugs can be administered by a variety of routes, including orally. Their oral bioavailability is indeed the most obvious advantage over biologics in drug development. |
| Organiser : Nathalie Mazure |
| Speakers : Nathalie Mazure | Frédéric Bost | Amandine Rovini |
Brief Teaser
Cancer cells require a continuous supply of nutrients to support their rapid division and abnormal growth. However, when they are deprived of a major energy source, such as glucose (sugar), they are able to adapt and exploit other sources to continue to grow. In fact, the tumor cell does not have essential gene changes that would explain its metabolic changes, it simply adapts its metabolic capacities to its priority needs. It appears, today, that the tumor cell orients its metabolism according to its specific needs. Recent advances in cancer biology have revealed that, in addition to glucose, amino acids are essential nutrients to satisfy the high metabolic demand of tumors. Indeed, the need for nucleic acid synthesis takes precedence over the strictly energetic needs, and the pentose pathway becomes a privileged pathway for glucose utilization. The tumor microenvironment, the niche, in which the tumor is encapsulated is also crucial in the "metabolic choice" of the tumor. It will be based on the intrinsic metabolism of the tumor but also on the exchanges between tumor cells and non-tumor cells, the cellular heterogeneity as well as the presence or absence of nutrients and/or oxygen. This great tumor complexity has been the subject of much attention for many years now and certain therapeutic avenues have been and are still being pursued. This session aims to shed light on the latest metabolic and therapeutic advances in the field of solid cancer. |
| Organiser : Grégoire Prevost |
| Speakers : Willy Mathot |
Brief Teaser
Register for half a day to benefit from the experience of the experts and entrepreneurs of life science leadership school (LSLEAD.COM) who will address the fundamentals and the essentials of what it takes to be a successful start up CEO or CSO. Assess the quality of your and competition’s project(s) and underlying Intellectual property Evaluate the market accessibility of your invention Maintain your target product profile and your business plan updated Improve your communication skills Get to talk finance, legal and cash and prepare for negotiation Raise funds, think big numbers and understand the reasoning of investors Assemble a dream team and rely on experienced consultants All the above (and more are missing) are of equal utmost importance. However brilliant and smart you are, should you “Go Start-up” you should be educated. It does not compare to anything you have been through. This session will help you determine yourself “startup” or “non startup”. For more information on LS LEAD, see www.lslead.com |
| Organiser : Grégoire Prevost |
| Speakers : Hélène Castel-gandolfo | Julien Hanson | Frédéric Simonin | Ralf Jockers | Erika Cecon | Eric Reiter | Hélène Demene |
Brief Teaser
G protein-coupled receptors (GPCRs) are among the most important protein families in sensing environmental changes at the cellular level providing adequate response and adaptation to them. Seminal discoveries elucidated over the last 20 years the basic signaling modules and the structural basis of the signal transmission of GPCRs. Their enormous potential as drug targets has been recognized with 30- 40% of currently marketed drugs targeting GPCRs and many others remaining to explored. The pioneering discoveries in the GPCR field have been recognized by several Nobel Prizes, the last one in 2012.
Lectures of the two GPCR WORKSHOPS will be given by world-class experts and cover the latest discoveries in the GPCR field, in terms of conceptional advances such as biased signaling, photopharmacology, structural biology, molecular insights in G protein and beta-arrestin coupling and function, the physiological role of GPCRs in circadian and seasonal rhythm regulation and in pain and the therapeutic potential of GPCR for the treatment of glioblastoma, metabolic disorders and macular degeneration.
The two WORKSHOPS are organized in collaboration with the International Research Network (IRN) i-GPCRnet (http://www.i-gpcrnet.com/) of which all speakers are members of. |
| Organiser : Grégoire Prevost |
| Speakers : Hélène Castel-gandolfo | Julien Hanson | Frédéric Simonin | Ralf Jockers | Erika Cecon | Eric Reiter | Hélène Demene |
Brief Teaser
G protein-coupled receptors (GPCRs) are among the most important protein families in sensing environmental changes at the cellular level providing adequate response and adaptation to them. Seminal discoveries elucidated over the last 20 years the basic signaling modules and the structural basis of the signal transmission of GPCRs. Their enormous potential as drug targets has been recognized with 30- 40% of currently marketed drugs targeting GPCRs and many others remaining to explored. The pioneering discoveries in the GPCR field have been recognized by several Nobel Prizes, the last one in 2012.
Lectures of the two GPCR WORKSHOPS will be given by world-class experts and cover the latest discoveries in the GPCR field, in terms of conceptional advances such as biased signaling, photopharmacology, structural biology, molecular insights in G protein and beta-arrestin coupling and function, the physiological role of GPCRs in circadian and seasonal rhythm regulation and in pain and the therapeutic potential of GPCR for the treatment of glioblastoma, metabolic disorders and macular degeneration.
The two WORKSHOPS are organized in collaboration with the International Research Network (IRN) i-GPCRnet (http://www.i-gpcrnet.com/) of which all speakers are members of. |
| Organiser : Hélène Castel-gandolfo |
| Speakers : Hélène Castel-gandolfo | Sylvain Fisson |
Brief Teaser
Brain tumors are rather diverse including more than 100 different types and subtypes for primary tumors alone, for which the etiologies are virtually unknown and the biological mechanisms still poorly understood. Among them, glioblastoma (GBM) remains one of the most aggressive cancers. Despite the most complete surgical resection, followed by radiation with concomitant and adjuvant chemotherapy, the median overall survival of patients is only 15 months with a 5-year survival rate of less than 10%. Thus, despite surgery, radiotherapy and chemotherapy, this adult brain cancer is often incurable. On the clinical and fundamental levels, multiple challenges remain both on i) fundamental aspects which will shed light on the natural history of the disease and oncogenicity (predispositions, microenvironment,...), intra- and inter-tumor heterogeneity, impact of the microenvironment, resistance to treatments and ii) patient quality of life and preservation of brain tissue and cognitive functions under treatments. The Permanent Health conferences 2022 of IBBS at Rouen University will focus on heterogeneity in gliomas during tumor progression, its dependency towards the microenvironment, its links with physicochemical characteristics as well as the matrix components interacting with the tumor, including highly vascularized areas and hypoxic/necrotic regions. We will address the dialogue between glioma and the brain nerve system via migration/invasion along blood vessels and white matter tracts, brain matrix and immune components |
| Organiser : Hélène Castel-gandolfo |
| Speakers : Hélène Castel-gandolfo |
Brief Teaser
Brain tumors are rather diverse including more than 100 different types and subtypes for primary tumors alone, for which the etiologies are virtually unknown and the biological mechanisms still poorly understood. Among them, glioblastoma (GBM) remains one of the most aggressive cancers. Despite the most complete surgical resection, followed by radiation with concomitant and adjuvant chemotherapy, the median overall survival of patients is only 15 months with a 5-year survival rate of less than 10%. Thus, despite surgery, radiotherapy and chemotherapy, this adult brain cancer is often incurable. On the clinical and fundamental levels, multiple challenges remain both on i) fundamental aspects which will shed light on the natural history of the disease and oncogenicity (predispositions, microenvironment,...), intra- and inter-tumor heterogeneity, impact of the microenvironment, resistance to treatments and ii) patient quality of life and preservation of brain tissue and cognitive functions under treatments. The Permanent Health conferences 2022 of IBBS at Rouen University will focus on heterogeneity in gliomas during tumor progression, its dependency towards the microenvironment, its links with physicochemical characteristics as well as the matrix components interacting with the tumor, including highly vascularized areas and hypoxic/necrotic regions. We will address the dialogue between glioma and the brain nerve system via migration/invasion along blood vessels and white matter tracts, brain matrix and immune components |
| Organiser : Dmitriy Klyuyev |
| Speakers : |
Brief Teaser
The key role of genetic factors in carcinogenesis is obvious, and to date, a number of genetic changes associated with certain tumor processes have been identified. A significant gap in the incidence of cancer pathology between rural and urban residents (the latter is significantly higher) was previously explained, in part, by unequal diagnostic capabilities. Modern diagnostic methods and wide coverage of screening measures, along with their availability for rural and urban residents, have not significantly reduced the gap in morbidity rates. This fact may indirectly indicate a significant contribution of environmental factors to carcinogenesis. The leveling of negative environmental effects is largely determined by the genes of the xenobiotic biotransformation system, which neutralize potentially mutagenic factors that affect the body. In the educational part of the session, biomarkers of oncological diseases and the possibilities of studying gene polymorphism in the diagnosis of oncological diseases, assessing the degree of risk of their development and the possibility of applying this knowledge in the development of personalized medicine will be considered. The research part of the session will be devoted to work in the direction of the study of gene polymorphism in various pathologies Through recent years research in KMU was focused on colorectal cancer. That is a part of wider efforts dedicated to development of personalized approaches for diagnosis, prognosis, prevention and treatment of various diseases. Most cases of CRC are sporadic and develop slowly over years. Genetic variation of single nucleotide polymorphisms and environmental risk factors are contributing in the etiology of CRC. It is known, that SNPs can vary among ethnic groups and brings a part of probability to the development of pathology. One of the research work goals was to seek for polymorphisms associated with the development of colorectal adenocarcinoma in representatives of the Kazakhstan population. Also machine learning methods prediction of CRC based on genetic data has been proposed as a promising platform for the development of genetic-based diagnostics. |
